Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Position Lessened by Sentry Investment Management LLC

Sentry Investment Management LLC cut its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 9.7% during the 4th quarter, HoldingsChannel reports. The firm owned 1,101 shares of the medical equipment provider’s stock after selling 118 shares during the quarter. Sentry Investment Management LLC’s holdings in Zimmer Biomet were worth $134,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently made changes to their positions in ZBH. Fairfield Bush & CO. acquired a new position in Zimmer Biomet during the 1st quarter worth $111,000. United Bank lifted its holdings in Zimmer Biomet by 4.1% in the first quarter. United Bank now owns 11,072 shares of the medical equipment provider’s stock worth $1,416,000 after purchasing an additional 437 shares during the period. Panagora Asset Management Inc. grew its position in Zimmer Biomet by 153.9% in the 1st quarter. Panagora Asset Management Inc. now owns 9,803 shares of the medical equipment provider’s stock valued at $1,254,000 after buying an additional 5,942 shares in the last quarter. Aviva PLC increased its stake in Zimmer Biomet by 0.4% during the 1st quarter. Aviva PLC now owns 30,636 shares of the medical equipment provider’s stock valued at $3,918,000 after buying an additional 137 shares during the period. Finally, Allianz Asset Management GmbH raised its position in shares of Zimmer Biomet by 11.2% during the 1st quarter. Allianz Asset Management GmbH now owns 41,816 shares of the medical equipment provider’s stock worth $5,348,000 after buying an additional 4,224 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Wall Street Analysts Forecast Growth

ZBH has been the topic of a number of research analyst reports. JPMorgan Chase & Co. raised their price objective on shares of Zimmer Biomet from $115.00 to $125.00 and gave the company a “neutral” rating in a research note on Friday, February 9th. Raymond James lifted their target price on Zimmer Biomet from $133.00 to $137.00 and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. Barclays upped their price target on shares of Zimmer Biomet from $120.00 to $130.00 and gave the company an “underweight” rating in a report on Monday, February 12th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $140.00 price objective on shares of Zimmer Biomet in a research note on Friday, February 9th. Finally, TheStreet raised shares of Zimmer Biomet from a “c” rating to a “b-” rating in a research note on Thursday, February 8th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $139.39.

Insider Buying and Selling

In other Zimmer Biomet news, VP Chad F. Phipps sold 26,156 shares of the business’s stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the completion of the transaction, the vice president now owns 44,145 shares of the company’s stock, valued at $5,677,929.90. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.95% of the stock is owned by corporate insiders.

Zimmer Biomet Price Performance

Zimmer Biomet stock opened at $121.30 on Thursday. The stock’s fifty day moving average price is $126.47 and its two-hundred day moving average price is $119.10. The firm has a market cap of $24.92 billion, a PE ratio of 24.81, a price-to-earnings-growth ratio of 2.24 and a beta of 1.01. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.61 and a quick ratio of 0.78. Zimmer Biomet Holdings, Inc. has a one year low of $102.00 and a one year high of $149.25.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 EPS for the quarter, beating the consensus estimate of $2.15 by $0.05. The firm had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.93 billion. Zimmer Biomet had a net margin of 13.85% and a return on equity of 12.79%. The business’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same period last year, the firm earned $1.88 EPS. As a group, research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.07 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.79%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 19.63%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.